HepaSH Sustainable Human Hepatocytes

Powered by CIEM

Marketed WW by Biopredic International

HepaSH Features

Sustainability
Consistency
Robustness
Functional performance
Long-Term Viability
Multidonor set
Zero stock policy
Data base

HepaSH Technology

HepaSH Standardization Technology

HepaSH Morphology and Life Style

Hepatic markers expression

HepaSH Metabolically Competent HH

HepaSH CYP Inducibility

Transporters

HepaSH Production and Shipment Schedule

HepaSH Donor Information

Fresh Suspended Ready-to-plate HepaSH

FSSH001: 5.106 cell/vial  1x 96-multi well plate

Provided as fresh suspended hepatocytes
3 donors available as of now

Donor 1: Female, Caucasian, 12 years old. Donor 2: Male, Caucasian, 3 months. Donor 3: Male, Caucasian, 5 years old
William E- based cell culture medium
Can be maintained for up to 14 days in 2D culture
2 production sessions/month
Our commitments: cell viability, number of viable cells, human cell percentage, sterility

Our services on HepaSH human hepatocytes

HepaSH® Scientific Publications

Explore scientific publications validating the performance and relevance of the HepaSH® model across various research applications.

View publications

News

BIOPREDIC

Mar 22, 2026

SOT 2026 — Society of Toxicology (SOT) 65th Annual Meeting & ToxExpo

BIOPREDIC

Feb 20, 2026

SSX India, Annual conference of the Society for the Study of Xenobiotics (SSX)

SSX India

EUROSAFE

Feb 5, 2026

TMG Visit — Tokyo Expansion Project

View all